Announcement of new MASC Trials CEO

Aileen Boyd-Squires

Melanoma and Skin Cancer Trials (MASC Trials) is delighted to announce the appointment of Aileen Boyd-Squires as Chief Executive of MASC Trials Ltd and Head of the MASC Research Centre at Monash University. Aileen brings a wealth of experience with more than 20 years in executive roles in the medical research, not-for-profit and commercial sectors and a clear vision for the next phase of our growth. She joins us from her most recent role as Chief Executive of the Children’s Cancer Foundation. She was previously Director of Research Partnerships at Murdoch Children’s Research Institute and Publishing Director with Wiley. She has rich experience in building high performing business units across Australia, Europe and Asia.

“It is a privilege to lead this important organisation,” Aileen said. “MASC Trials is ideally placed to support the critical next phase of investigator-initiated clinical trials in melanoma and skin cancer and I am excited to work with our partners and investigators to build relationships and deliver high quality services. I am looking forward to leading the vital work of MASC Trials in improving disease prevention and patient care on a global scale.”

Aileen is working closely with Libby Paton – who has led MASC Trials since 2008 – during our leadership transition through to December 2020. Prof. Mark Shackleton, Chairman of Melanoma and Skin Cancer Trials said, “More information will follow soon about Libby’s remarkable contributions to MASC Trials over that transformative period, including in guiding its recent and exciting evolution from ANZMTG to the incorporated entity that is now overseeing a more extensive, diverse and well-funded trials portfolio than ever. In the meantime, I hope you will join me and the Board of MASC Trials in wishing Libby well into the future.”